CR7854A - Dihidrofenantridinosulfonamidas sustituidas - Google Patents

Dihidrofenantridinosulfonamidas sustituidas

Info

Publication number
CR7854A
CR7854A CR7854A CR7854A CR7854A CR 7854 A CR7854 A CR 7854A CR 7854 A CR7854 A CR 7854A CR 7854 A CR7854 A CR 7854A CR 7854 A CR7854 A CR 7854A
Authority
CR
Costa Rica
Prior art keywords
dihydrophenantridinosulphonamids
substituted
arthritis
diseases
useful
Prior art date
Application number
CR7854A
Other languages
English (en)
Inventor
Albert John Molinari
Mark Anthony Ashwell
Brian Hugh Ridgway
William Jay Moore
Amedeco Arturo Failli
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32474616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR7854(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR7854A publication Critical patent/CR7854A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion proporciona un compuesto de las formulas (I) o (II) que tiene la estructura o una sal farmaceuticamente aceptable de el que son utiles para el tratamiento del componente inflamatorio de enfermedades y son particularmente utiles en el tratamiento de aterosclerosis, infarto de miocardio, inflamatoria, artritis, diabetes tipo II, y enfermedades autoinmunes como esclerosis multiple y artritis reumatoide.
CR7854A 2002-12-04 2005-06-02 Dihidrofenantridinosulfonamidas sustituidas CR7854A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43094902P 2002-12-04 2002-12-04
US10/718,461 US6894061B2 (en) 2002-12-04 2003-11-20 Substituted dihydrophenanthridinesulfonamides

Publications (1)

Publication Number Publication Date
CR7854A true CR7854A (es) 2006-04-28

Family

ID=32474616

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7854A CR7854A (es) 2002-12-04 2005-06-02 Dihidrofenantridinosulfonamidas sustituidas

Country Status (19)

Country Link
US (1) US6894061B2 (es)
EP (1) EP1567502B1 (es)
JP (1) JP4465280B2 (es)
KR (1) KR20050085321A (es)
AT (1) ATE370934T1 (es)
AU (1) AU2003298819A1 (es)
BR (1) BR0316196A (es)
CA (1) CA2508329A1 (es)
CR (1) CR7854A (es)
DE (1) DE60315874T2 (es)
DK (1) DK1567502T3 (es)
EC (1) ECSP055832A (es)
ES (1) ES2291739T3 (es)
MX (1) MXPA05006003A (es)
NO (1) NO20053204L (es)
NZ (1) NZ540440A (es)
RU (1) RU2005118070A (es)
TW (1) TW200510322A (es)
WO (1) WO2004050631A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119276A1 (en) * 2003-09-24 2005-06-02 Wyeth Methods of treating inflammatory bowel disease using NF-kB inhibitors
US20050113405A1 (en) * 2003-09-24 2005-05-26 Wyeth Methods of treating rheumatoid arthritis using NF-kB inhibitors
EP1652841A1 (en) * 2004-04-30 2006-05-03 Switch Biotech Aktiengesellschaft Novel phenantridine analogues and their use as inhibitors of hyperproliferation of T cells and/or keratinocytes
CN1968932A (zh) * 2004-06-18 2007-05-23 惠氏公司 制备6－烷基－5－芳基磺酰基－二氢菲啶的方法
US7304073B2 (en) * 2004-08-20 2007-12-04 Wyeth Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors
CN101052623A (zh) * 2004-09-02 2007-10-10 惠氏公司 作为细胞因子调节剂的菲啶羰基酚类
US7555415B2 (en) 2005-01-19 2009-06-30 Wyeth Methods for the design of estrogen receptor ligands
HU230518B1 (hu) * 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
UY31832A (es) 2008-05-20 2010-01-05 Astrazeneca Ab Derivados de indazol sustituidos con fenilo y benzodioxinilo
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2016179343A1 (en) * 2015-05-05 2016-11-10 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
WO2020117894A1 (en) * 2018-12-05 2020-06-11 The Board Of Trustees Of The University Of Illinois Isocarbostyril alkaloids and functionalization thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1135947A (en) 1965-04-20 1968-12-11 Aspro Nicholas Ltd Novel biologically active derivatives of phenanthridone
US5153185A (en) 1991-04-16 1992-10-06 Merck & Co., Inc. 2-phenanthridonyl carbapenems
EP0509756A1 (en) 1991-04-16 1992-10-21 Merck & Co. Inc. 2-Phenanthridonyl carbapenems having cationizeable substituents
CA2066132A1 (en) 1991-04-16 1992-10-17 Thomas A. Rano 2-phenanthridonyl carbapenems
US5726186A (en) 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
PT1000035E (pt) 1997-07-25 2003-04-30 Altana Pharma Ag 6-fenilfenantridinas substituidas
EE05105B1 (et) 1999-01-15 2008-12-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Fenlfenantridiinid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
ATE356810T1 (de) 1999-01-15 2007-04-15 Altana Pharma Ag Polysubstituted 6-phenylphenanthridines mit pde- iv hemmender wirkung
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
WO2002005616A1 (en) 2000-07-14 2002-01-24 Altana Pharma Ag Novel 6-phenylphenanthridines
US6777446B2 (en) 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators

Also Published As

Publication number Publication date
JP4465280B2 (ja) 2010-05-19
DK1567502T3 (da) 2007-10-29
WO2004050631A1 (en) 2004-06-17
ECSP055832A (es) 2005-08-11
US20040167155A1 (en) 2004-08-26
BR0316196A (pt) 2005-09-27
DE60315874D1 (de) 2007-10-04
ATE370934T1 (de) 2007-09-15
RU2005118070A (ru) 2006-01-27
JP2006510631A (ja) 2006-03-30
KR20050085321A (ko) 2005-08-29
DE60315874T2 (de) 2008-05-15
NO20053204L (no) 2005-09-05
CA2508329A1 (en) 2004-06-17
AU2003298819A1 (en) 2004-06-23
ES2291739T3 (es) 2008-03-01
TW200510322A (en) 2005-03-16
EP1567502B1 (en) 2007-08-22
NO20053204D0 (no) 2005-06-30
US6894061B2 (en) 2005-05-17
EP1567502A1 (en) 2005-08-31
NZ540440A (en) 2006-11-30
MXPA05006003A (es) 2005-08-18

Similar Documents

Publication Publication Date Title
MXPA05011581A (es) Derivados de acido 3-(1-naftil)-2-cianopropanoico como ligandos receptores de estrogenos.
ECSP055832A (es) Dihidrofenantridinosulfonamidas sustituidas
MX2010003612A (es) Derivados de oxadiazol.
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
DE60333387D1 (de) Triazolopyridazine als proteinkinase-inhibitoren
EA201070423A1 (ru) Диарильные соединения оксадиазолов
TR200201187T2 (tr) Ters transkriptazın inhibitörleri olarak benzofenonlar
NO20050199L (no) Azadisyklo-oktan og nonanderivater med DDP-IV-inhiberende aktivitet
CY1111363T1 (el) Τρικυκλικος ανταγωνιστης υποδοχεων θρομβινης
BR9811599A (pt) Compostos de dipetìdeo que inibem adesão de leucócito mediada por vla-4
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
EA200501274A1 (ru) Пиразолы и способы их получения и применения
NO20000450L (no) Substituerte fenylalaninforbindelser som inhiberer leukocytt- adhesjon mediert av VLA-4
ATE385238T1 (de) Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände
DE60226154D1 (de) Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
ATE240328T1 (de) Substituierte azaoxindolederivate
UA85559C2 (en) Aminobenzophenone compounds
ATE413388T1 (de) Muskarin antagonisten
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
NO20070089L (no) DPP-IV inhibitorer
WO2006004924A3 (en) Imidazolo-related compounds, compositions and methods for their use
ATE346040T1 (de) Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit
NO20053562L (no) Nye aminobenzofenonforbindelser
DE50200864D1 (de) Verbundelemente enthaltend bitumen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)